Cell and gene therapies are witnessing rapid advancements, but significant barriers to commercialization remain. These include regulatory hurdles, high costs, and safety concerns. To ensure these therapies reach as many patients as possible, researchers must consider business models early in the development process.
Automation enhances efficiency and minimizes contamination risks and labor costs. Despite the initial investment in automation equipment, the long-term savings can be significant. Explore how progress in automation could potentially expand the accessibility and benefits of T-cell therapies to a larger patient population.
As more T-cell therapies come to market, the quality and scale of treatments are set up to improve. Recent research reveals that modifying T cells could potentially cure autoimmunity disorders, a shift from the previous view of T cells as the cause of such diseases.
Cell and gene therapy developers and researchers no longer have to rely on a highly manual and variable process. Now they can finish strong with precise, consistent results for suspension cells and adherent cells.
Automate the right way, right from the start with the Quantum Flex Cell Expansion System. Gain the flexibility, scalability and connectivity to grow with your therapy, from process development to commercial manufacturing.
